RE:RE:RE:RE:All comers dose and safety vs targeting high sortlin expressSomehow, you always overlook the IMMU potential this stock holds - the potential for stratospheric returns if the Sort1+ platform becomes a real thing and it is moving closer to that being a real possibility everyday. It is why those who own it are not selling.
Unless I am missing something, there are only 230,000 additional $0.38 options coming due by 12/20/22. 105,000 left from Lafond and 125,000 from Marsolais.
Regarding the share price the new head of IR has apparently told management to be prepared to do a boatload of investor meetings over the next year. If they have compelling data from phase 1b and move into a phase 2 trial over that same time frame, then the stock is defintely going to be moving a lot higher and a lot of buyers will juice the volume. I am not sure there will be a lot of sellers under those circumstnaces, so the stock could jump a lot. If they don't have compelling cancer data, however, no amount of meetings IR sets up is going to make much of a difference.
We got better phase 1a data than I expected (I had low expectations, so three responders, low free docetaxel, a responder who had failed on docetaxel and another taxane, among other tidbits was more than I hoped for). Directionally, TH-1902 is pointing to a good outcome for phase 1b, but they have to produce the data to get things rolling and to have a lot to talk about on all thsoe investor meetings.
Biobob wrote: Longer.. and 500k options coming du in dec. 2022..... no liquidity... sucks unless they can do something about the sh..tty stock price...